Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

NCT07220642 · tracked via the Priya Life Science UK tracker

Sponsor

Novo Nordisk A/S

Phase

Phase 3

Started

2025-11-05

Last updated

2026-08-06

Condition(s) studied

ObesityOverweight

Investigational drug(s) / intervention(s)

CagrilintidePlacebo

Cagrilintide: Cagrilintide will be administered subcutaneously with a pen-injector as an adjunt to lifestyle intervention counselling.

Placebo: Placebo matched to cagrilintide will be administered subcutaneously with a pen-injector as an adjunt to lifestyle intervention counselling.

Study summary

This study will look at how much cagrilintide helps people with overweight or obesity lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participants will either get cagrilintide or placebo. Which treatment participants get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. Possible side effects will be followed carefully during the study. For each participant, the study will last for about 1 year and 6 months.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study * Female or male (sex at birth) * Age 18 years or above at the time of signing the informed consent * History of at least one self-reported unsuccessful dietary effort to lose body weight (a\*) * Body mass index (BMI) greater than or equal to \>= 30.0 kilogram per square meter (kg/m\^2), or BMI greater than or equal to \>= 27.0 kg/m\^2 with the presence of at least one weight related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease (a\*) Exclusion criteria: * History of type 1 or type 2 diabetes (a\*) * Treatment, or intention to initiate treatment, with any medication prescribed for the indication of weight management within 180 days before screening (a\*) * Previous dosing of marketed or non-marketed amylin-based compounds (a\*) (a\*) - As declared by the participant, reported in the medical records or at the investigator's discretion.

Primary outcome measure(s)

Relative change in body weight — From baseline (week 0) to end of treatment (week 64)
Measured as percentage (%).

Trial sites (40)

Facility	City	Region
Diablo Clinical Research, Inc.	Walnut Creek	California
Univ of Colorado at Denver	Aurora	Colorado
Florida Inst For Clin Res LLC	Orlando	Florida
Oviedo Medical Research, LLC	Oviedo	Florida
Walgreens - Store 11760	Oak Park	Illinois
Midwest Inst For Clin Res	Indianapolis	Indiana
StudyMetrix Research LLC	City of Saint Peters	Missouri
PharmQuest Life Sciences LLC	Greensboro	North Carolina
Selma Medical Associates	Winchester	Virginia
CIPREC Pueyrredon	Buenos Aires	Argentina
CEDIC Centro de Investigación Clínica	CABA	Argentina
Sydney Cardiometabolic Centre	Liverpool	New South Wales
Hunter Diabetes Centre	Merewether	New South Wales
G.A. Research Associates Ltd.	Moncton	New Brunswick
Nova Scotia Hlth Halifax	Halifax	Nova Scotia
Hamilton Medical Research Group	Hamilton	Ontario
Wharton Medical Clinic Clinical Trials (Hamilton)	Hamilton	Ontario
Milestone Research	London	Ontario
Centricity Research Oshawa	Oshawa	Ontario
Centricity Research Toronto	Toronto	Ontario
Centricity Research Mirabel	Mirabel	Quebec
Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec	Saint-Herblain	France
Centre de Recherche Clinique Portes Du Sud	Vénissieux	France
InnoDiab Forschung GmbH	Essen	Germany
Wendisch - Dahl Hamburg - DZHW	Hamburg	Germany
RED-Institut für medizinische Forschung und Fortbildung GmbH	Oldenburg in Holstein	Germany
Fondazione Policlinico Universitario Agostino Gemelli IRCS	Rome	RM
AOUP Giaccone Palermo	Palermo	Sicily
A.O.U. Bologna_ Policlinico S.Orsola Malpighi	Bologna	Italy
IRCCS Ospedale San Raffaele Milano	Milan	Italy
Haukeland Universitetssykehus	Bergen	Norway
Drammen sykehus - Vestre Viken HF	Drammen	Norway
St. Olavs Hospital HF_Endokrinologisk avdeling	Trondheim	Norway
Osteo-Medic s.c. A. Racewicz, J. Supronik	Bialystok	Poland
Care Clinic Sp. z o. o.	Katowice	Poland
Terpa Sp. z o.o. Sp. k.	Lublin	Poland
NBR Polska Tomasz Klodawski	Warsaw	Poland
Oak Tree Surgery	Liskeard	Cornwall
North Coast Medical Ltd	Newquay	Cornwall
Brunel Medical Practice	Torquay	Devon

More Novo Nordisk A/S trials in the UK

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors Active, not recruiting

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity Recruiting

A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN Enrolling by invitation

Adverse Event Data Collection From External Registries on Nonacog Beta Pegol Enrolling by invitation

A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A Active, not recruiting

Other trials for the same condition

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity Recruiting

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) Recruiting

A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK) Recruiting

A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body Active, not recruiting

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07220642 on ClinicalTrials.gov ↗ ← All trials in the UK